Tool May Predict Short-Term Progression to Type 1 Diabetes

May be useful for assessing preventive treatments in autoantibody-positive relatives

FRIDAY, March 20, 2015 (HealthDay News) -- Researchers have developed a new tool that may predict short-term glycemic progression to type 1 diabetes (T1D). The findings were published online March 10 in Diabetes Care.

Jay M. Sosenko, M.D., from the University of Miami, and colleagues utilized Diabetes Prevention Trial-Type 1 (DPT-1) data to develop and test a scale to serve as a potential end point for six-month glycemic progression (PS6M) toward type 1 diabetes (T1D) in autoantibody-positive relatives of individuals with T1D.

The researchers found that PS6M significantly predicted T1D (P < 0.001). Compared to the baseline-to-six-month difference in glucose, the area under the receiver operating characteristic curve was greater (P < 0.001) for the PS6M. In those with two or more autoantibodies, PS6M values were higher (30-0 min C-peptide values <2.00 ng/mL, or DPT-1 Risk Scores >7.00; P < 0.001 for all).

"The PS6M is an indicator of short-term glycemic progression to T1D that could be a useful tool for assessing preventive treatments and biomarkers," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician’s Briefing Staff

Physician’s Briefing Staff

Published on March 20, 2015

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ